Assessment of Cerebrovascular Autoregulation in Head-Injured Patients
A Validation Study

Luzius A. Steiner, MD; Jonathan P. Coles, FRCA; Andrew J. Johnston, FRCA; Doris A. Chatfield, BSc; Peter Smielewski, PhD; Tim D. Fryer, PhD; Franklin I. Aigbirhio, PhD; John C. Clark, PhD, DSc; John D. Pickard, MChir, FRCS, FMedSci; David K. Menon, MD, PhD, FRCA, FRCP, FMedSci; Marek Czosnyka, PhD, DSc

Background and Purpose—Cerebrovascular autoregulation is frequently measured in head-injured patients. We attempted to validate 4 bedside methods used for assessment of autoregulation.

Methods—PET was performed at a cerebral perfusion pressure (CPP) of 70 and 90 mm Hg in 20 patients. Cerebral blood flow (CBF) and cerebral metabolic rate for oxygen (CMR_O2) were determined at each CPP level. Patients were sedated with propofol and fentanyl. Norepinephrine was used to control CPP. During PET scanning, transcranial Doppler (TCD) flow velocity in the middle cerebral artery was monitored, and the arterio-jugular oxygen content difference (AJD_O2) was measured at each CPP. Autoregulation was determined as the static rate of autoregulation based on PET (SROR_PET) and TCD (SROR_TCD) data, based on changes in AJD_O2, and with 2 indexes based on the relationship between slow waves of CPP and flow velocity (mean velocity index, Mx) and between arterial blood pressure and intracranial pressure (pressure reactivity index, PRx).

Results—We found significant correlations between SROR_PET and SROR_TCD (r²=0.32; P<0.01) and between SROR_PET and PRx (r²=0.31; P<0.05). There were no significant associations between PET data and autoregulation as assessed by changes in AJD_O2. Global CMR_O2 was significantly lower at the higher CPP (P<0.01).

Conclusions—Despite some variability, SROR_TCD and PRx may provide useful approximations of autoregulation in head-injured patients. At least with our methods, CMR_O2 changes with the increase in CPP; hence, flow-metabolism coupling may affect the results of autoregulation testing. (Stroke. 2003;34:2404-2409.)

Key Words: autoregulation ■ brain injuries ■ monitoring, physiologic ■ tomography, emission computed

Cerebrovascular autoregulation is defined as the brain's ability to keep cerebral blood flow (CBF) relatively constant despite changes in cerebral perfusion pressure (CPP). This mechanism is frequently disturbed after head injury, even when the injury is only mild,1,2 and poor autoregulation after head injury is associated with unfavorable outcome.3-5 suggesting that this mechanism is a powerful protector of the injured brain against perfusion pressure-related secondary insults. It has also been suggested that targeting CPP according to an index of autoregulation might allow determination of an individual optimal CPP after head injury.6 Therefore, determination of autoregulation is of clinical interest in patients with traumatic brain injury.

Determination of autoregulation depends on an accurate assessment of CBF, which can be difficult. There are many methods available to measure CBF in head-injured patients, but many bedside methods do not measure CBF but instead monitor a surrogate marker considered to be proportional to CBF.7 In clinical practice, transcranial Doppler (TCD) is commonly used for dynamic⁵ and static⁶ measurements of autoregulation, although some investigators have used arterio-jugular oxygen content difference (AJD_O2)⁷ or methods based on waveform analysis.⁴,¹¹ When autoregulation is determined at the bedside, the assumption is made that the cerebral metabolic rate for oxygen (CMR_O2) does not change during autoregulation testing. The validity of this assumption is critical, because changes in CMR_O2 would mean that the measurement would reflect both autoregulation and flow-metabolism coupling. Measurement of static autoregulation requires a change in CPP, and vasoactive drugs such as norepinephrine are used to achieve this change. However, such drugs may influence cerebral metabolism, especially in head-injured patients, in whom the blood-brain barrier is potentially damaged. In view of these shortcomings, it is
important to validate the techniques we currently use to determine autoregulation. So far, some of these methods have been compared against each other, and Larsen et al. have validated TCD for determination of the lower limit of autoregulation in healthy volunteers. However, there has been no validation of these methods in brain-injured patients against a gold standard such as PET.

By simultaneously measuring autoregulation with bedside methods and with PET, we attempted to validate 4 bedside methods to determine autoregulation in acutely head-injured patients: the static rate of autoregulation (SROR) based on TCD, a method based on AJDO2, and 2 methods based on waveform analysis.

### Patients and Methods

The local research ethics committee approved this study. Informed consent was obtained from the next of kin of all patients. All patients admitted to our Neurosciences Critical Care Unit with severe (admission Glasgow Coma Score [GCS] ≤8) or moderate (admission GCS ≤12) traumatic brain injury, with secondary neurological deterioration requiring intubation and mechanical ventilation, were eligible for inclusion in this study. Exclusion criteria were rapidly evolving space-occupying lesions, and barbiturate infusions (2 patients). However, no patient had received mannitol or hypertonic saline within the 6 hours preceding the study. All patients required catecholamines to maintain baseline CPP. Mean arterial pressure (MAP) and ICP were monitored by use of standard kits for invasive blood pressure monitoring (Baxter Healthcare Corp, CardioVascular Group) and intraparenchymal pressure transducers (Codman MicroSensors ICP Transducer, Codman & Shurtleff Inc).

Two sets of PET scans were performed, each assessing CBF and CMRO2. CPP was controlled with an infusion of norepinephrine that was adjusted to reach the desired CPP and then as necessary to keep CPP constant during scanning. The first scan (baseline) was carried out at a CPP of 69 ± 6 mm Hg; the second (intervention), at a CPP of 92 ± 4 mm Hg. Because of the change in CPP, ICP increased from 18 ± 6 to 19 ± 6 mm Hg (P < 0.01). Arterial partial pressure of CO2 (PaCO2) was measured at 5 time points during each scan, and PaCO2 was kept stable by adjusting the ventilator as necessary. Variability of PaCO2 during acquisition of CBF data for individual patients is shown in Table 1. The precision of PaCO2 control is limited not only by the respiratory status of the patients but also by the precision of the blood gas analyzer. For all blood gas measurements, an AVL Omnis blood gas analyzer (AVL Graz, A-8020 Austria) was used. The total precision of this analyzer according to NCCLS document EP5-T is SD ≤2.75% (personal communication, J. Riegebauer, AVL Graz, 2002). PaCO2 during the baseline scan was 4.41 ± 0.33 kPa and during the intervention scan was 4.48 ± 0.34 kPa (P = 0.07).

Patient temperature was kept constant with the use of a heating/cooling mattress at the level desired by the team responsible for the clinical management. Patient temperature at baseline and at intervention was 35.4 ± 0.7°C (P = 0.4).

### PET Methods

The studies were undertaken on a General Electric Advance scanner (GE Medical Systems). The steady-state protocol used has been described in detail previously. Emission images were coregistered to spiral CT images obtained immediately after PET scanning. All emission data were normalized to Talairach space.17 CBF and CMRO2 were calculated globally and from the middle cerebral artery (MCA) territory for each hemisphere separately. The MCA territory was defined using high specificity at the cost of sensitivity: All pixels that may have been within the MCA territory were shown in Table 1. The precision of PaCO2 control is limited not only by the respiratory status of the patients but also by the precision of the blood gas analyzer. For all blood gas measurements, an AVL Omniblood gas analyzer (AVL Graz, A-8020 Austria) was used. The total precision of this analyzer according to NCCLS document EP5-T is SD ≤0.27 kPa (personal communication, J. Riegebauer, AVL Graz, 2002). PaCO2 during the baseline scan was 4.41 ± 0.33 kPa and during the intervention scan was 4.48 ± 0.34 kPa (P = 0.07).

### Transcranial Doppler

Bilateral TCD (DWL Multidop X4, DWL Elektronische Systeme GmbH) of the MCA was performed throughout scanning with two 2-MHz probes held in place with a head rack. Phantom testing carried out in the PET scanner before the patient studies established that there were no image artifacts caused by the ultrasound probes and head rack.

### Determination of Autoregulation

For comparison of PET- and TCD-based determinations of autoregulation, SROR was used. SROR is calculated as the percent change in cerebrovascular resistance divided by the percent change in CPP used to induce the change in resistance. Results are expressed as percentage, with 0% representing complete autoregulatory failure and 100% representing optimal autoregulation. The formula is shown in the Appendix, which is available online at http://stroke.ahajournals.org. For calculation of SROR based on PET data (SRORPET), CBF from the MCA territory and CPP were used as inputs into the formula. SRORPET was calculated using mean flow velocity (FVM) instead of CBF. For comparison of PET and TCD, only FVM and CPP acquired during the phase of the PET scan during which CBF data were acquired were used.

<table>
<thead>
<tr>
<th>TABLE 1. Patient Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
</tr>
<tr>
<td>----</td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
<tr>
<td>8</td>
</tr>
<tr>
<td>9</td>
</tr>
<tr>
<td>10</td>
</tr>
<tr>
<td>11</td>
</tr>
<tr>
<td>12</td>
</tr>
<tr>
<td>13</td>
</tr>
<tr>
<td>14</td>
</tr>
<tr>
<td>15</td>
</tr>
<tr>
<td>16</td>
</tr>
<tr>
<td>17</td>
</tr>
<tr>
<td>18</td>
</tr>
<tr>
<td>19</td>
</tr>
<tr>
<td>20</td>
</tr>
</tbody>
</table>

Day indicates day after injury; GCS, admission GCS; CT, classification based on CT CT2; GOS, Glasgow Outcome Scale; PaCO2, mean ± SD of 2 CBF scans; EML, evacuated mass lesion; MD, moderate disability; DII/III, diffuse injury II/III; GR, good recovery; SD, severe disability; NA, outcome data not available; and D, dead.
During both scans, AJDo$_2$ was calculated from paired arterial and jugular blood samples withdrawn immediately before the H$_2$O infusion was started and used to calculate the percent change in CBF. According to the Fick principle, if CMRO$_2$ is constant, then the percentage decrease in AJDo$_2$ will equal the percentage increase in CBF, which can be compared with the percent change in global CBF as measured by PET. The formula is shown in the Appendix.

Two methods based on waveform analysis were investigated. The first method calculates an index of pressure reactivity from the analysis of spontaneous slow waves of MAP and ICP. Average values of MAP and ICP were calculated for 6-second intervals and used to calculate a pressure reactivity index (PRx) every 60 seconds as the linear moving correlation coefficient between 40 consecutive values of MAP and ICP. Possible values therefore range from −1 to 1. Negative or zero values indicate intact pressure reactivity; positive values indicate disturbed pressure reactivity. Pressure reactivity is a key component of autoregulation, and intact autoregulation implies intact pressure reactivity. The second method calculates a mean velocity index ($Mx$). This index is based on changes in FVm in the MCA evoked by spontaneous slow waves of CPP. The same algorithm is applied as described above for calculation of PRx, but FVm and CPP are used as input functions. Possible values range from −1 to 1. $Mx \leq 0$ represents intact autoregulation; $Mx > 0$ implies impaired autoregulation. For comparisons between PET data and PRx or $Mx$, the last 2 variables were averaged over the complete duration of scanning at the higher level of CPP (≈90 mm Hg), because sampling over longer time periods improves the estimation of these parameters.

The value at the higher CPP was chosen because these measures of dynamic autoregulation would clearly have been nonconcordant at the 2 CPP levels and a consideration of cerebrovascular physiology shows that dynamic measures at the higher CPP value more closely represent the SROR that interrogated autoregulatory efficiency across the interval of CPP values that we studied. For comparisons between PRx and PET CBF, global CBF was used, whereas MCA territory CBF was used for the comparison with $Mx$.

Data were sampled from the analog output of the hemodynamic monitors, processed through an analog-to-digital converter (DT 2814, Data Translation Marlboro), and stored on a computer using software developed in house. Sampling frequency was 30 Hz. Time-averaged means for MAP, ICP, and CPP (CPP = MAP − ICP) were calculated and stored every 6 seconds. In 1 patient, we were unable to synchronize the left MCA; therefore, for comparisons between TCD and PET, data from 39 hemispheres were available. Because of unavailability of monitoring equipment, data from 17 patients were available for comparisons between PRx, $Mx$, and PET. In 2 patients, technical problems prevented us from collecting CMRO$_2$ data; therefore, CMRO$_2$ data from 18 patients were available for analysis. Data are presented as mean ± SD unless otherwise indicated. Linear correlations and Bland Altman plots were used to assess associations and agreement of measurement methods as appropriate. Calculations were performed with SPSS 11.0 (SPSS Inc). A value of $P < 0.05$ was considered statistically significant.

### Results

PET and TCD data are presented in Table 2. TCD FVm correlated significantly with PET CBF in both hemispheres (CPP = 70 mm Hg; left, $r^2 = 0.24$, $P = 0.03$; right, $r^2 = 0.33$, $P < 0.01$; pooled, $r^2 = 0.23$, $P = 0.002$; CPP = 90 mm Hg; left, $r^2 = 0.33$, $P = 0.01$; right, $r^2 = 0.36$, $P < 0.01$; pooled, $r^2 = 0.34$, $P = 0.0001$; Figure 1). However, there was marked variability that limits the usefulness of TCD as an estimator of absolute CBF. The change in CBF correlated with the change in FVm (left, $r^2 = 0.48$, $P = 0.001$; right, $r^2 = 0.42$, $P < 0.01$). There was a significant correlation between SROR$_{PET}$ and SROR$_{TCD}$ (left, $r^2 = 0.53$, $P < 0.001$; right, $r^2 = 0.32$, $P < 0.01$), suggesting that SROR$_{TCD}$ is a useful approximation of autoregulation within the MCA territory (Figure 2a). The Bland Altman plot

<table>
<thead>
<tr>
<th>Table 2. Physiological Data</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
</tr>
<tr>
<td>CBF (global), mL · 100 mL⁻¹ · min⁻¹</td>
</tr>
<tr>
<td>CBF (MCA), mL · 100 mL⁻¹ · min⁻¹</td>
</tr>
<tr>
<td>FVm, cm · s⁻¹</td>
</tr>
<tr>
<td>ΔCBF, mL · 100 mL⁻¹ · min⁻¹</td>
</tr>
<tr>
<td>ΔFVm, cm · s⁻¹</td>
</tr>
<tr>
<td>SROR$_{PET}$, %</td>
</tr>
<tr>
<td>SROR$_{TCD}$, %</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD. FVm values represent data collected during PET CBF measurements.

(Figure 2b) shows that SROR$_{TCD}$ measurements are on average 30% lower than SROR$_{PET}$ measurements, and again there is a large variability.

AJDo$_2$ at baseline was normal or low, making global ischemia unlikely. However, increases in CPP resulted in a significant fall in AJDo$_2$ (4.0 ± 1.2 to 3.2 ± 1.1 mL · dL⁻¹; $P < 0.001$), implying poor flow-metabolism coupling. There was no significant relationship between the estimated percent change in CBF based on AJDo$_2$ and the percent change in global CBF determined by PET ($P = 0.6$).

PRx was significantly associated with global SROR$_{PET}$ ($r^2 = 0.31$, $P = 0.02$), with the relationship very close for low values of SROR but less so for those >80% (Figure 3). There was no significant relationship between SROR$_{PET}$ and $Mx$ in either hemisphere.

The correlation between PET and TCD did not appear to be confounded by the presence of lesions within the MCA territory. When MCA territories were grouped as lesioned or not lesioned, the association for each subset was not significantly better than for the pooled data ($r^2 = 0.45$, 0.23, and 0.23, respectively, and widely overlapping 95% confidence intervals for the regression). Similarly, this stratification resulted in no significant improvement in the association of SROR measured with the 2 techniques.

Global CMRO$_2$ decreased significantly when CPP was raised (72.3 ± 12.5 versus 69.1 ± 9.8 μmol · 100 mL⁻¹ · min⁻¹; $P = 0.008$). Within the MCA territories, CMRO$_2$ decreased significantly in nonlesioned (79.5 ± 14.0 versus 76.5 ± 10.1 μmol · 100 mL⁻¹ · min⁻¹; $P = 0.03$) and lesioned (66.3 ± 13.2 versus 62.8 ± 12.2 μmol · 100 mL⁻¹ · min⁻¹; $P = 0.04$) regions of interest. The reduction in MCA territories containing lesions was not significantly different from that observed in MCA territories without a lesion.

### Discussion

We found that some but not all bedside measurements provide useful estimates of autoregulation. However, we observed a large variability even when significant associations were present. CMRO$_2$ was not identical at the 2 levels of CPP; thus, measurements may reflect not only autoregulation but also variable flow-metabolism coupling.

Our study has 2 major methodological limitations. First, we use a very specific, albeit standard, clinical management strategy. This limits the transfer of our results to centers that use distinctly different management strategies. The second limitation is the independence of PET CBF.
important limitation is that, because of the precision of PET, which is strongly influenced by the low signal-to-noise ratio of the method, interpretation of results in patients with small changes in CBF, ie, good autoregulation, may be difficult. Despite reasonable overall agreement of data, measurements in patients with good autoregulation and therefore small changes in CBF are more likely to be influenced by noise. With our PET methods, the SD of repeated CBF measurements under constant physiology from the MCA territory in head injured patients is 1.7 mL · 100 mL⁻¹ · min⁻¹ (unpublished data). This is illustrated in Figure 4, which shows that the agreement between PET and TCD measurements of SROR is better when patients with very low changes in CBF are excluded. This is further supported by Figure 3, which shows that the relationship between PET and PRx is close for low values of SROR but less so for high values of SROR. This suggests that a comparison of methods in patients with good autoregulation is affected not only by the sensitivity of the bedside methods to detect small changes in CBF but also by the precision and signal-to-noise ratio of PET. This also shows that it would be impossible to perform a validation in healthy volunteers with our methods.

Our data suggest that the percent change in AJD O₂⁻¹ is not a reliable estimator of changes in CBF and therefore not a useful estimator of autoregulation. This may be due in part to the fact that the key assumption of constant CMRO₂ was not fulfilled. These changes in CMR O₂ associated with norepinephrine-induced CPP increases were often small but may be

Figure 1. Relationship between CBF and blood flow velocity. CBF was measured with PET. All measurements were made at a CPP of ~70 mm Hg. Dashed line represents linear regression function for pooled data.

Figure 2. Relationship between static rate of autoregulation measured by PET and TCD. Dashed line represents linear regression function for pooled data. Despite the significant correlation between PET and TCD, the Bland Altman plot (b) shows marked variability. This could limit the usefulness of the TCD-based assessment. However, much of this variability is due to data points in the higher range of SROR. The reason for this could be that measurements of small changes in CBF are strongly influenced by the low signal-to-noise ratio of PET.
particularly relevant with respect to estimates of autoregulation based on metabolism (eg, $AJD_O_2$ measurements) as opposed to those based purely on an estimate of CBF (eg, $SRO_R_{TCD}$).

We have not been able to validate $Mx$. There are several possible explanations for this. Earlier work has shown a close correlation between $Mx$ and $PRx$, which was not present in this group of patients. A selection bias could therefore have influenced our results. Alternatively, the number of investigated patients could be too low to establish this relationship. However, we suspect that our methods have prevented us from establishing a relationship between $Mx$ and changes in PET CBF. $Mx$ depends on spontaneous slow fluctuations of CPP of at least 5 mm Hg to elicit changes in $FVm$, whereas we tried to keep CPP as stable as possible and possibly suppressed the necessary slow waves to a relevant extent or created overly abrupt changes in CPP with some of the changes in the norepinephrine infusion rate. Our results suggest that an index based on MAP and ICP is more robust than one based on $FVm$ and CPP. This is supported by data from an other group that also used waveform analysis for quantification of autoregulation.

The decrease in $CMR_O_2$ that we observed with the increase in CPP is unexpected. For $CMR_O_2$, the SD for repeated scans is $1.3 \mu mol \cdot 100 mL^{-1} \cdot min^{-1}$ (unpublished data); therefore, the reductions, albeit small, are likely not to be due to the limited sensitivity or noise of the PET scan. We can only speculate on the reasons for this decrease in $CMR_O_2$. One possible explanation is that the $CMR_O_2$ changes are due to the clinical management, with propofol delivery increased at the higher CPP. Alternatively, it could be a specific effect of norepinephrine or of a disrupted blood-brain barrier. Regard-

![Figure 3. Relationship between static rate of autoregulation measured by PET and PRx.](image3)

![Figure 4. Effect of small changes in CBF. This Bland Altman plot illustrates the effect of small changes in CBF and their influence on the agreement between SROR measured with TCD and PET. Excluding CBF changes $<1.7 mL \cdot 100 mL^{-1} \cdot min^{-1}$ improves the agreement considerably. Axes are scaled as in Figure 2b to enable direct comparison.](image4)
less of the underlying mechanism, this reduction in CMRO₂ is likely to lead to a reduction in CBF and thus an overestimation of autoregulation. The extent of the error will depend on the degree of flow-metabolism coupling, which may be disrupted to a variable degree after head injury.²⁵,²⁸ Bedside methods do not allow us to quantify this reliably.

In conclusion, the static rate of autoregulation calculated from TCD data and PRx provide useful information on autoregulation in head-injured patients. Studies grading autoregulation on that basis of changes in AJD₀₂ need to be interpreted with caution. PRx seems to be a more robust estimator of autoregulation than Mx. More data are needed to validate Mx. At least when our methods are used, all measurements may be influenced by flow-metabolism coupling.²⁹

Acknowledgments

Dr Steiner was supported by a Myron B. Laver Grant (Department of Anesthesia, University of Basel, Switzerland), by a grant from the Margarete and Walter Lichtenstein-Stiftung (Basel, Switzerland), and by the Swiss National Science Foundation; he was recipient of an Overseas Research Student Award (Committee of Vice-Chancellors and Principals of the Universities of the United Kingdom). Dr Coles was funded by a Wellcome Research Training Fellowship and by a Beverley and Raymond Sackler Studentship Award. Dr Johnston was supported by a grant from Codman. Dr Czosnyka is on leave from the Warsaw University of Technology, Poland. This project was supported by the UK Government Technology Foresight Initiative and the Medical Research Council (Grant No G9439390 ID 65883). We thank Dr Neil Harris (Academic Neurosurgery and Centre for Brain Repair, University of Cambridge, UK) for supplying the middle cerebral artery territory templates.

References

Assessment of Cerebrovascular Autoregulation in Head-Injured Patients: A Validation Study

Luzius A. Steiner, Jonathan P. Coles, Andrew J. Johnston, Doris A. Chatfield, Peter Smielewski, Tim D. Fryer, Franklin I. Aigbirhio, John C. Clark, John D. Pickard, David K. Menon and Marek Czosnyka

Stroke. 2003;34:2404-2409; originally published online August 28, 2003;
doi: 10.1161/01.STR.000089014.59668.04

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/34/10/2404

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/